biostudies-literatureUnknown10(17)Wei YF<b>Introduction</b>: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a standard first-line treatment for advanced <i>EGFR</i>-mutated NSCLC patients. Factors associated with symptoms and quality of life (QOL) improvements have not been investigated. <b>Methods</b>: We conducted a multicenter, prospective study to evaluate improvements in QOL and symptoms in NSCLC patients treated with first-line EGFR-TKIs. QOL was assessed using the instrument of Functional Assessment of Cancer Therapy-Lung questionnaire (FACT-L) and Treatment Outcome Index (TOI). Assessment of symptoms was evaluated using the Lung cancer subscale (LCS). <b>Results</b>: Eligible subjects included 280 patients for endpoint analyses. The mean FACT-L score increased by 4.0 ± 15.56 at Week 2 (p<0.00Journal of Cancer4151-4158https://www.ebi.ac.uk/biostudies/studies/S-EPMC6692623biostudies-literatureFactors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with <i>EGFR</i>-mutated non-small-cell lung cancer - A multicenter prospective SMILE study.PMC6692623Huang WTChang CCLin CMWu MFKo JCWei YFShieh JMLiu TCLin CHHsia TCChian CFfalseFactors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with <i>EGFR</i>-mutated non-small-cell lung cancer - A multicenter prospective SMILE study.<b>Introduction</b>: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a standard first-line treatment for advanced <i>EGFR</i>-mutated NSCLC patients. Factors associated with symptoms and quality of life (QOL) improvements have not been investigated. <b>Methods</b>: We conducted a multicenter, prospective study to evaluate improvements in QOL and symptoms in NSCLC patients treated with first-line EGFR-TKIs. QOL was assessed using the instrument of Functional Assessment of Cancer Therapy-Lung questionnaire (FACT-L) and Treatment Outcome Index (TOI). Assessment of symptoms was evaluated using the Lung cancer subscale (LCS). <b>Results</b>: Eligible subjects included 280 patients for endpoint analyses. The mean FACT-L score increased by 4.0 ± 15.56 at Week 2 (p<0.002019-01-01T00:00:00Z20192025-04-21T17:19:15.417Z2019-08-21T07:02:42ZS-EPMC66926233141766010.7150/jca.30507